A single-center, single-arm, observational study to evaluate the tolerability and efficacy of carfilzomib-based therapy for antibody mediated rejection in adult patients with lung transplant recipients

Trial Profile

A single-center, single-arm, observational study to evaluate the tolerability and efficacy of carfilzomib-based therapy for antibody mediated rejection in adult patients with lung transplant recipients

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Lung transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Apr 2017 Results (n=19) presented at the 37th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
    • 07 Feb 2017 Results (n=14) assessing effect of carfilzomib on antibody mediated rejection of the pulmonary allografts, published in the American Journal of Transplantation
    • 30 Apr 2016 Results (n=16) assessing the impact of pre-treatment donor specific HLA antibody titer on the carfilzomib-based therapy efficacy presented at the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top